Compare Becton Dickinson and Co (BDX) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Micron Technology, Inc. — how do they compare? Becton Dickinson and Co trades at $156.18 (market cap $41.51B), while Micron Technology, Inc. trades at $904.56 (market cap $1.11T). The key difference: Micron Technology, Inc. is far larger — about 26.7× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | MU | |
|---|---|---|
Market Cap | $41.51B | $1.11T |
Sector | Health | Technology |
52-Week High | $185.39 | $1.21K |
52-Week Low | $135.49 | $104.88 |
Enterprise Value | $57.97B | $1.09T |
Dividend Yield | 2.79% | 0.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Micron Technology (MU) trades at $937.00, down 4.32% today, but maintains strong bullish technical momentum with support near $924. The company demonstrates robust fundamentals, with Q1 2026 EPS beating estimates at $25.11 versus $20.98 expected, and revenue growth accelerating to $37.38 billion in 2025. Analyst sentiment remains overwhelmingly positive, with 81% recommending Buy and a consensus price target of $1,550.
Outlook is favorable driven by AI memory demand and pricing power, though risks include competitive pressure from SK Hynix and cyclical semiconductor volatility. Cash flow trends show strengthening operational performance, with net cash flow turning positive at $2.59 billion in 2025, supporting future growth investments and shareholder returns via dividends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
